Akademik Veri Yönetim Sistemi
Transfusion and Apheresis Science, cilt.65, sa.2, 2026 (SCI-Expanded, Scopus)
Pooled granulocyte concentrates (PGCs) prepared from whole blood donors without requiring pharmacological pretreatment represent an innovative approach that stands out with its donor safety, cost-effectiveness, and ease of clinical application. However, due to limited clinical data, it is open to further research. This retrospective study aimed to evaluate the effects of PG suspension applications on infection control and hematological parameters in pediatric hematology-oncology patients. Forty-nine pediatric patients who received PG suspensions at the Pediatric Hematology-Oncology and Bone Marrow Transplantation Centers of Erciyes University Faculty of Medicine between 2019 and 2024 were included in the study. The PGCs were transfused to patients according to clinical indications by pooling a certain number of residual leukocytes obtained from blood donors using a fully automated blood separation device (Reveos, Terumo). In a comparison of pre- and post-treatment hematologic parameters, statistically significant increases were found in white blood cell (WBC), hemoglobin (Hb), neutrophil count (NE), neutrophil percentage (NE%), monocytes (M), immature granulocytes (IG), and red blood cell count (RBC) (p < 0.05). No significant differences were found in C-Reactive Protein (CRP), platelet (PLT), or lymphocyte levels. Significant improvements were observed in hematologic parameters, particularly in the first two units, and the gradual decrease in CRP levels demonstrated that infection control was achieved. The findings suggest that PGCs obtained with the Reveos whole blood separation system and used as a pooled treatment may be an effective and safe supportive treatment option for infection control and hematologic improvement in severely neutropenic pediatric patients.